With 40 years of executive leadership in medical device and health care services, David Perez serves as an independent board member and advisor to over a dozen corporations and non-profit organizations. His expertise encompasses growing a highly regulated global business, leading within a variety of foreign, public and private equity ownership structures as well as strategic planning, enterprise risk management, culture development and talent planning.

Perez retired from his leadership role at Terumo BCT in March 2019 following a comprehensive 2-year succession and transition plan. During his more than 18 years serving as president and CEO, Terumo BCT grew from $160M in global revenue to $1B as a mission-driven biomedical company focused on unlocking the potential of blood and cell-based therapies in the blood banking, transfusion medicine and cell therapy/regenerative medicine sectors.

Beginning with COBE BCT in 1999, through Gambro BCT, CaridianBCT, and then Terumo BCT, Perez guided the company through several foreign ownership structures, leveraging his extensive experience leading complex, multinational businesses and diverse, cross-cultural organizations. Under his tenure, the company grew from a single manufacturing and R&D site to employing over 7,000 associates at five regional headquarters, five R&D centers and six manufacturing plants located in the U.S., Ireland, Belgium, Japan, Vietnam and India. His strategic vision took the organization from two business units, focused on two product platforms, into global leadership positions in five business areas and 12 product categories serving customers and patients in 130 countries, with 70% of the company revenue coming from international customers.

As CEO of CaridianBCT, under the private equity ownership of EQT and Investor AB, Perez and his global team increased company value by 85% over 4.5 years, resulting in a $2.6B exit to Terumo Corporation (4543.T. Nikkei) in June 2011. Perez continued to lead the company for 8 more years, also serving on the Terumo Corporation Board of Directors until June 2019, where he was one of fewer than 300 non-Japanese board members of all publicly traded companies in Japan.